Condition
Diabetic Macular Edema (DME)
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 15 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
15 shownA Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular EdemaNCT07812090 · 2026-08-21
RECRUITINGCorticosteroid for Diabetic Macular Edema (DME) StudyNCT07843849 · 2026-04-07
RECRUITINGBiomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar RanibizumabNCT07520045 · 2026-03-12
RECRUITINGHigh Dose Aflibercept in Diabetic Macular Edema in Patients With Previous VitrectomyNCT06662994 · 2025-07-07
RECRUITINGInvestigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South WalesNCT06914778 · 2025-03-31
RECRUITINGImpact of Intravitreal Faricimab on Renal Function in Diabetic PatientsNCT06929507 · 2025-03-10
RECRUITINGPhase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)NCT07842016 · 2026-10-15
NOT_YET_RECRUITINGPhase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)NCT07841899 · 2026-10-15
NOT_YET_RECRUITINGStudy Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsNCT07456826 · 2026-03-31
ENROLLING_BY_INVITATIONComparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract SurgeryNCT07301775 · 2026-01-01
NOT_YET_RECRUITINGAI Prediction of Treatment Response in DMENCT07707856 · 2025-05-15
COMPLETEDAn Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World SettingNCT06398080 · 2024-12-12
WITHDRAWNSafety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)NCT04857996 · 2021-06-25
COMPLETEDSafety and Bioactivity of AXT107 in Subjects With Diabetic Macular EdemaNCT04697758 · 2020-12-10
TERMINATEDPhotobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease PreventionNCT03859245 · 2019-02-23
UNKNOWNCommon interventions
AfliberceptDRUG2OLN324DRUG2ShamOTHER2Aflibercept (Eylea)DRUG1aflibercept 8 mgDRUG1Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)DRUG1Anti-VEGFDRUG1Artificial Intelligence-Based Imaging AnalysisOTHER1AXT107 0.1 mgDRUG1AXT107 0.25 mgDRUG1AXT107 0.5 mgDRUG1Biosimilar ranibizumabDRUG1Blood draw for the laboratory assessmentOTHER1Chloroprocaine Ophthalmic Gel 3% (IHEEZO)DRUG1FaricimabDRUG1Intravitreal dexamethasone implantDRUG1Intravitreal injection of Faricimab or Aflibercept 2 mgDRUG1Ketogenic dietBEHAVIORAL1Lidocaine Hydrochloride Injection 2%DRUG1Oral BGE-102DRUG1Oral Placebo Matching BGE-102DRUG1PhotobiomodulationBEHAVIORAL1Proparacaine Hydrochloride Ophthalmic Solution 0.5%DRUG1Sham Subconjunctival InjectionPROCEDURE1UBX1325DRUG1
Leading sponsors
Ollin Biosciences, Inc.
2
Ahmad Zeeshan Jamil
1
AsclepiX Therapeutics, Inc.
1
Benha University
1
BioAge Labs, Inc.
1
Bristlecone Health, Inc.
1
Harrow Inc
1
Hywel Dda Health Board
1
Osijek University Hospital
1
Regeneron Pharmaceuticals
1
Retina Consultants of Orange County
1
Unity Biotechnology, Inc.
1
University Hospital, Alexandroupolis
1
Vanderbilt University Medical Center
1
Trial status mix
RECRUITING6
NOT_YET_RECRUITING3
COMPLETED2
ENROLLING_BY_INVITATION1
TERMINATED1
UNKNOWN1
WITHDRAWN1
Phase mix
PHASE44
NA3
PHASE23
PHASE32
PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.